Noetik uses transformer AI models like TARIO-2 to address the 95% failure rate in cancer drug trials by reframing the problem as one of patient-treatment matching.

95% of cancer treatments fail during clinical trials, representing a massive inefficiency in drug development

Noetik founders Ron Alfa and Daniel Bear argue the high failure rate stems from a matching problem rather than drug efficacy issues

The company is deploying autoregressive transformers, specifically TARIO-2, to better match patients with appropriate cancer treatments

This AI approach could potentially improve trial success rates by optimizing patient selection and treatment pairing